<VariationArchive VariationID="7834" VariationName="NM_000314.8(PTEN):c.40dup (p.Arg14fs)" VariationType="Duplication" Accession="VCV000007834" Version="6" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-02-14" DateCreated="2018-06-30" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="22873" VariationID="7834">
      <GeneList>
        <Gene Symbol="PTEN" FullName="phosphatase and tensin homolog" GeneID="5728" HGNC_ID="HGNC:9588" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>10q23.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="10" Accession="NW_013171807.1" start="79449" stop="187719" display_start="79449" display_stop="187719" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="87863625" stop="87971930" display_start="87863625" display_stop="87971930" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="89623194" stop="89728531" display_start="89623194" display_stop="89728531" Strand="+" />
          </Location>
          <OMIM>601728</OMIM>
          <Haploinsufficiency last_evaluated="2020-06-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTEN">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-06-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTEN">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000314.8(PTEN):c.40dup (p.Arg14fs)</Name>
      <CanonicalSPDI>NC_000010.11:87864505:AAAA:AAAAA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>10q23.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="87864505" stop="87864506" display_start="87864505" display_stop="87864506" variantLength="1" positionVCF="87864505" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="89624262" stop="89624263" display_start="89624262" display_stop="89624263" variantLength="1" positionVCF="89624262" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
      </Location>
      <ProteinChange>R14fs</ProteinChange>
      <ProteinChange>R187fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_311" sequenceAccession="LRG_311">
            <Expression>LRG_311:g.6071dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1087" sequenceAccession="LRG_1087">
            <Expression>LRG_1087:g.3932dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000010.10" sequenceAccession="NC_000010" sequenceVersion="10" change="g.89624266dup" Assembly="GRCh37">
            <Expression>NC_000010.10:g.89624266dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000010.11" sequenceAccession="NC_000010" sequenceVersion="11" change="g.87864509dup" Assembly="GRCh38">
            <Expression>NC_000010.11:g.87864509dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007466.2" sequenceAccession="NG_007466" sequenceVersion="2" change="g.6071dup">
            <Expression>NG_007466.2:g.6071dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_033079.1" sequenceAccession="NG_033079" sequenceVersion="1" change="g.3932dup">
            <Expression>NG_033079.1:g.3932dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000314.8" sequenceAccession="NM_000314" sequenceVersion="8" change="c.40dup" MANESelect="true">
            <Expression>NM_000314.8:c.40dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000305.3" sequenceAccession="NP_000305" sequenceVersion="3" change="p.Arg14fs">
            <Expression>NP_000305.3:p.Arg14fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001304717.5" sequenceAccession="NM_001304717" sequenceVersion="5" change="c.559dup">
            <Expression>NM_001304717.5:c.559dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001291646.4" sequenceAccession="NP_001291646" sequenceVersion="4" change="p.Arg187fs">
            <Expression>NP_001291646.4:p.Arg187fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001304718.2" sequenceAccession="NM_001304718" sequenceVersion="2" change="c.-666dup">
            <Expression>NM_001304718.2:c.-666dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000314.6" sequenceAccession="NM_000314" sequenceVersion="6" change="c.40dupA">
            <Expression>NM_000314.6:c.40dupA</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000314.8" sequenceAccession="NM_000314" sequenceVersion="8" change="c.40dupA" MANESelect="true">
            <Expression>NM_000314.8:c.40dupA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA254258" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="601728.0022" DB="OMIM" />
        <XRef Type="rs" ID="587776671" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000314.8(PTEN):c.40dup (p.Arg14fs) AND Cowden syndrome 1" Accession="RCV000008282" Version="4">
        <ClassifiedConditionList TraitSetID="2119">
          <ClassifiedCondition DB="MedGen" ID="CN072330">Cowden syndrome 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2000-03-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000314.8(PTEN):c.40dup (p.Arg14fs) AND PTEN hamartoma tumor syndrome" Accession="RCV000735261" Version="4">
        <ClassifiedConditionList TraitSetID="2131">
          <ClassifiedCondition DB="MedGen" ID="C1959582">PTEN hamartoma tumor syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2018-04-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000314.8(PTEN):c.40dup (p.Arg14fs) AND not provided" Accession="RCV003493409" Version="1">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-02-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000314.8(PTEN):c.40dup (p.Arg14fs) AND Glioma susceptibility 2" Accession="RCV003460436" Version="1">
        <ClassifiedConditionList TraitSetID="2127">
          <ClassifiedCondition DB="MedGen" ID="C2751642">Glioma susceptibility 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-12-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2018-04-06" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2018-06-30" MostRecentSubmission="2024-02-14">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10777358</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2131" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10363" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PTEN Hamartomatous Tumour Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">PTEN hamartoma tumor syndrome</ElementValue>
                <XRef ID="MONDO:0017623" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PTEN-related disorders</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHTS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000552184" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552302" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558905" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000326160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551654" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12800" />
                <XRef ID="12800" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome. CS is a multiple hamartoma syndrome with a high risk for benign and malignant tumors of the thyroid, breast, kidney, and endometrium. Affected individuals usually have macrocephaly, trichilemmomas, and papillomatous papules, and present by the late 20s. The lifetime risk of developing breast cancer is 85%, with an average age of diagnosis between 38 and 46 years. The lifetime risk for thyroid cancer (usually follicular, rarely papillary, but never medullary thyroid cancer) is approximately 35%. The lifetime risk for renal cell cancer (predominantly of papillary histology) is 34%. The risk for endometrial cancer may approach 28%. BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis. PS is a complex, highly variable disorder involving congenital malformations and hamartomatous overgrowth of multiple tissues, as well as connective tissue nevi, epidermal nevi, and hyperostoses. Proteus-like syndrome is undefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS.</Attribute>
                <XRef ID="NBK1488" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301661</ID>
                <ID Source="BookShelf">NBK1488</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <Citation Type="general" Abbrev="NCCN, 2014">
                <ID Source="PubMed">25190698</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Genetics of Colorectal Cancer">
                <ID Source="PubMed">26389505</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <XRef ID="306498" DB="Orphanet" />
              <XRef ID="C1959582" DB="MedGen" />
              <XRef ID="D006223" DB="MeSH" />
              <XRef ID="MONDO:0017623" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2119" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="13756" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cowden syndrome 1</ElementValue>
                <XRef ID="MONDO:0008021" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CWS1</ElementValue>
                <XRef Type="MIM" ID="158350" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MHAM</ElementValue>
                <XRef Type="MIM" ID="158350" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome. CS is a multiple hamartoma syndrome with a high risk for benign and malignant tumors of the thyroid, breast, kidney, and endometrium. Affected individuals usually have macrocephaly, trichilemmomas, and papillomatous papules, and present by the late 20s. The lifetime risk of developing breast cancer is 85%, with an average age of diagnosis between 38 and 46 years. The lifetime risk for thyroid cancer (usually follicular, rarely papillary, but never medullary thyroid cancer) is approximately 35%. The lifetime risk for renal cell cancer (predominantly of papillary histology) is 34%. The risk for endometrial cancer may approach 28%. BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis. PS is a complex, highly variable disorder involving congenital malformations and hamartomatous overgrowth of multiple tissues, as well as connective tissue nevi, epidermal nevi, and hyperostoses. Proteus-like syndrome is undefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS.</Attribute>
                <XRef ID="NBK1488" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="274">gain of function</Attribute>
                <XRef ID="GTR000514929" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522278" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528059" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528912" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528914" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556509" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509012" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509038" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514990" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528377" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528910" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553541" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16450" />
                <XRef ID="16450" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301661</ID>
                <ID Source="BookShelf">NBK1488</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="pmc">3111012</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="CN072330" DB="MedGen" />
              <XRef ID="MONDO:0008021" DB="MONDO" />
              <XRef Type="MIM" ID="158350" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2127" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="6762" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Glioma susceptibility 2</ElementValue>
                <XRef ID="Glioma+susceptibility+2/8469" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013092" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GLM2</ElementValue>
                <XRef Type="MIM" ID="613028" DB="OMIM" />
              </Symbol>
              <XRef ID="182067" DB="Orphanet" />
              <XRef ID="C2751642" DB="MedGen" />
              <XRef ID="MONDO:0013092" DB="MONDO" />
              <XRef Type="MIM" ID="613028" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="28489" SubmissionDate="2018-06-27" DateLastUpdated="2018-06-30" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="601728.0022_COWDEN SYNDROME 1" title="PTEN, 1-BP INS, A_COWDEN SYNDROME 1" />
        <ClinVarAccession Accession="SCV000028489" DateUpdated="2018-06-30" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2000-03-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a patient with numerous manifestations of Cowden disease (CWS1; 158350) including fibroepithelial polyps and acanthosis nigricans, Raizis et al. (2000) found a single adenine insertion in exon 1 of the PTEN gene between position 40 and 41. The mutation results in a frameshift in codon 14 with protein truncation 29 amino acids later. This mutation, resulting in total disruption of the PTEN gene including the phosphatase and 5-prime tensin domain, was reported to be the most 5-prime mutation in the PTEN gene reported so far.</Attribute>
              <Citation>
                <ID Source="PubMed">10777358</ID>
              </Citation>
              <XRef DB="OMIM" ID="158350" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PTEN" />
          </GeneList>
          <Name>PTEN, 1-BP INS, A</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, A</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="601728.0022" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">COWDEN SYNDROME 1</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion FDARecognizedDatabase="true" ID="1680475" SubmissionDate="2018-12-03" DateLastUpdated="2022-12-11" DateCreated="2018-12-16">
        <ClinVarSubmissionID localKey="d7cc25c0-43b3-408c-8e19-6aab8d40a4f1" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV000863473" DateUpdated="2022-12-11" DateCreated="2018-12-16" Type="SCV" Version="3" SubmitterName="Clingen PTEN Variant Curation Expert Panel, Clingen" OrgID="506694" OrganizationCategory="consortium" OrgAbbreviation="CG_PTEN_EP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-04-06">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10777358</ID>
          </Citation>
          <Comment>PTEN c.40dupA (p.R14Kfs) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the "PTEN ACMG Specifications Summary" document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533). PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 10777358) PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 10777358)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ClinGen PTEN ACMG Specifications v1</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/qslnhwbd/pten_acmg_specifications_summary_v1.0_2018.pdf</URL>
            <CitationText>ClinGen_PTEN_ACMG_Specifications_v1.pdf</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PTEN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000314.6:c.40dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA306498" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB4873350</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7853846" SubmissionDate="2023-12-07" DateLastUpdated="2023-12-30" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_000314.8:c.40dup|OMIM:613028" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004204846" DateUpdated="2023-12-30" DateCreated="2023-12-30" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-12-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000314.8:c.40dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613028" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7927663" SubmissionDate="2024-02-06" DateLastUpdated="2024-02-14" DateCreated="2024-02-14">
        <ClinVarSubmissionID localKey="NM_000314.8:c.40dupA|not provided" />
        <ClinVarAccession Accession="SCV004243380" DateUpdated="2024-02-14" DateCreated="2024-02-14" Type="SCV" Version="1" SubmitterName="Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital" OrgID="505691" OrganizationCategory="laboratory" OrgAbbreviation="GM4113, RH" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PTEN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000314.8:c.40dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14210317</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1680475" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA306498" MappingRef="Orphanet">
        <MedGen CUI="C1959582" Name="PTEN hamartoma tumor syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7853846" TraitType="Disease" MappingType="XRef" MappingValue="613028" MappingRef="OMIM">
        <MedGen CUI="C2751642" Name="Glioma susceptibility 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7927663" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="28489" TraitType="Disease" MappingType="Name" MappingValue="COWDEN SYNDROME 1" MappingRef="Preferred">
        <MedGen CUI="CN072330" Name="Cowden syndrome 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

